[Therapeutic agents of today and the future for atopic dermatitis].
Ikoma
Akihiko
A
akiikoma@kuhp.kyoto-u.ac.jp
D000287:Administration, Topical; D000818:Animals; D018926:Anti-Allergic Agents / Q000008:administration & dosage; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage; D000982:Antipruritics / Q000008:administration & dosage; D003876:Dermatitis, Atopic / Q000188:drug therapy*; D015195:Drug Design; D005544:Forecasting; D005938:Glucocorticoids / Q000008:administration & dosage; D006634:Histamine H1 Antagonists / Q000008:administration & dosage; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D016328:NF-kappa B; D009838:Oligodeoxyribonucleotides / Q000008:administration & dosage; D016559:Tacrolimus / Q000008:administration & dosage
D018926:Anti-Allergic Agents; D000893:Anti-Inflammatory Agents; D000982:Antipruritics; D005938:Glucocorticoids; D006634:Histamine H1 Antagonists; D007166:Immunosuppressive Agents; D016328:NF-kappa B; D009838:Oligodeoxyribonucleotides; D016559:Tacrolimus